201
|
Bobbala S, Hook S. Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines? Pharm Res 2016; 33:2078-97. [DOI: 10.1007/s11095-016-1979-0] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Accepted: 06/21/2016] [Indexed: 12/16/2022]
|
202
|
Maji M, Mazumder S, Bhattacharya S, Choudhury ST, Sabur A, Shadab M, Bhattacharya P, Ali N. A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8(+) T Cells. Sci Rep 2016; 6:27206. [PMID: 27251373 PMCID: PMC4890172 DOI: 10.1038/srep27206] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Accepted: 05/17/2016] [Indexed: 12/13/2022] Open
Abstract
The most effective strategy for protection against intracellular infections such as Leishmania is vaccination with live parasites. Use of recombinant proteins avoids the risks associated with live vaccines. However, due to low immunogenicity, they fail to trigger T cell responses particularly of CD8+ cells requisite for persistent immunity. Previously we showed the importance of protein entrapment in cationic liposomes and MPL as adjuvant for elicitation of CD4+ and CD8+ T cell responses for long-term protection. In this study we investigated the role of cationic liposomes on maturation and antigen presentation capacity of dendritic cells (DCs). We observed that cationic liposomes were taken up very efficiently by DCs and transported to different cellular sites. DCs activated with liposomal rgp63 led to efficient presentation of antigen to specific CD4+ and CD8+ T cells. Furthermore, lymphoid CD8+ T cells from liposomal rgp63 immunized mice demonstrated better proliferative ability when co-cultured ex vivo with stimulated DCs. Addition of MPL to vaccine enhanced the antigen presentation by DCs and induced more efficient antigen specific CD8+ T cell responses when compared to free and liposomal antigen. These liposomal formulations presented to CD8+ T cells through TAP-dependent MHC-I pathway offer new possibilities for a safe subunit vaccine.
Collapse
Affiliation(s)
- Mithun Maji
- Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, India
| | - Saumyabrata Mazumder
- Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, India
| | - Souparno Bhattacharya
- Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, India
| | - Somsubhra Thakur Choudhury
- Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, India
| | - Abdus Sabur
- Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, India
| | - Md Shadab
- Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, India
| | - Pradyot Bhattacharya
- Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, India
| | - Nahid Ali
- Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, India
| |
Collapse
|
203
|
Cox F, Juraszek J, Stoop EJM, Goudsmit J. Universal influenza vaccine design: directing the antibody repertoire. Future Virol 2016. [DOI: 10.2217/fvl-2016-0045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Influenza infections are responsible for a large health and economic burden. Vaccination is the best strategy to reduce influenza-related disease burden, but current vaccines have limited breadth and need near-annual reformulation. Developing new influenza vaccines that provide broad and long-lasting protection is an important goal. This review represents an overview of the current knowledge of the universal vaccine approach that focuses on the induction of broadly neutralizing antibodies targeting the hemagglutinin (HA) stem of influenza viruses. Adjuvation of existing influenza vaccines has so far had limited effect on the induction of broadly neutralizing antibodies. HA stem-based immunogens that lack the immunodominant HA head have shown promising results in preclinical models, providing evidence that a universal influenza vaccine is within reach.
Collapse
Affiliation(s)
- Freek Cox
- Infectious Diseases & Vaccines Therapeutic Area, Janssen Research & Development, Archimedesweg 4-6, 2301 CA Leiden, The Netherlands
| | - Jarek Juraszek
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 4-6, 2301 CA Leiden, The Netherlands
| | - Esther JM Stoop
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 4-6, 2301 CA Leiden, The Netherlands
| | - Jaap Goudsmit
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 4-6, 2301 CA Leiden, The Netherlands
| |
Collapse
|
204
|
Krause RGE, Grobler AF, Goldring JPD. Comparing Antibody Responses in Chickens Against Plasmodium falciparum Lactate Dehydrogenase and Glyceraldehyde-3-phosphate Dehydrogenase with Freund's and Pheroid® Adjuvants. Immunol Invest 2016; 44:627-42. [PMID: 26436851 DOI: 10.3109/08820139.2015.1070268] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Pheroid® technology was assessed as an alternative to Freund's adjuvant to raise antibodies in experimental animals. Chickens were immunized with two recombinantly expressed Plasmodium falciparum proteins, lactate dehydrogenase (PfLDH) and glyceraldehyde-3-phosphate dehydrogenase (PfGAPDH), alone or in combination with Freund's adjuvant or Pheroid®. Chicken egg yolk antibodies (IgY) were isolated and compared for specificity, sensitivity and yield. Freund's adjuvant and Pheroid® stimulated prolonged antibody responses in chickens against both antigens. Affinity purified antibodies had specificity for the recombinant and the native proteins on Western blots. Antibodies generated in the presence of Freund's adjuvant had high sensitivity for both antigens. Pheroid® generated antibodies that detected the lowest concentration of recombinant PfLDH. Freund's adjuvant and Pheroid® both improved chicken IgY yields, with Pheroid® showing a 2-fold increase relative to controls. Pheroid® was well-tolerated in chickens and has potential for development as a safe adjuvant for testing alternative stimulatory factors to improve adjuvant formulations.
Collapse
Affiliation(s)
- Robert G E Krause
- a Department of Biochemistry , University of KwaZulu-Natal , Scottsville , South Africa and
| | - Anne F Grobler
- b DST/NWU Preclinical Drug Development Platform, Faculty of Health Sciences, North-West University , Potchefstroom , South Africa
| | - J P Dean Goldring
- a Department of Biochemistry , University of KwaZulu-Natal , Scottsville , South Africa and
| |
Collapse
|
205
|
Liu J, Li R, Liu K, Li L, Zai X, Chi X, Fu L, Xu J, Chen W. Identification of antigen-specific human monoclonal antibodies using high-throughput sequencing of the antibody repertoire. Biochem Biophys Res Commun 2016; 473:23-28. [PMID: 26979754 DOI: 10.1016/j.bbrc.2016.03.038] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Accepted: 03/08/2016] [Indexed: 12/26/2022]
Abstract
High-throughput sequencing of the antibody repertoire provides a large number of antibody variable region sequences that can be used to generate human monoclonal antibodies. However, current screening methods for identifying antigen-specific antibodies are inefficient. In the present study, we developed an antibody clone screening strategy based on clone dynamics and relative frequency, and used it to identify antigen-specific human monoclonal antibodies. Enzyme-linked immunosorbent assay showed that at least 52% of putative positive immunoglobulin heavy chains composed antigen-specific antibodies. Combining information on dynamics and relative frequency improved identification of positive clones and elimination of negative clones. and increase the credibility of putative positive clones. Therefore the screening strategy could simplify the subsequent experimental screening and may facilitate the generation of antigen-specific antibodies.
Collapse
Affiliation(s)
- Ju Liu
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
| | - Ruihua Li
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
| | - Kun Liu
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
| | - Liangliang Li
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
| | - Xiaodong Zai
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
| | - Xiangyang Chi
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
| | - Ling Fu
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
| | - Junjie Xu
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
| | - Wei Chen
- Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
| |
Collapse
|
206
|
Frahm GE, Pochopsky AWT, Clarke TM, Johnston MJW. Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant. PLoS One 2016; 11:e0150229. [PMID: 26925777 PMCID: PMC4771808 DOI: 10.1371/journal.pone.0150229] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Accepted: 02/10/2016] [Indexed: 11/24/2022] Open
Abstract
Microflow digital imaging (MDI) has become a widely accepted method for assessing sub-visible particles in pharmaceutical formulations however, to date; no data have been presented on the utility of this methodology when formulations include opaque vaccine adjuvants. This study evaluates the ability of MDI to assess sub-visible particles under these conditions. A Fluid Imaging Technologies Inc. FlowCAM® instrument was used to assess a number of sub-visible particle types in solution with increasing concentrations of AddaVax™, a nanoscale squalene-based adjuvant. With the objective (10X) used and the limitations of the sensor resolution, the instrument was incapable of distinguishing between sub-visible particles and AddaVax™ droplets at particle sizes less than 5 μm. The instrument was capable of imaging all particle types assessed (polystyrene beads, borosilicate glass, cellulose, polyethylene protein aggregate mimics, and lysozyme protein aggregates) at sizes greater than 5 μm in concentrations of AddaVax™ up to 50% (vol:vol). Reduced edge gradients and a decrease in measured particle sizes were noted as adjuvant concentrations increased. No significant changes in particle counts were observed for polystyrene particle standards and lysozyme protein aggregates, however significant reductions in particle counts were observed for borosilicate (80% of original) and cellulose (92% of original) particles. This reduction in particle counts may be due to the opaque adjuvant masking translucent particles present in borosilicate and cellulose samples. Although the results suggest that the utility of MDI for assessing sub-visible particles in high concentrations of adjuvant may be highly dependent on particle morphology, we believe that further investigation of this methodology to assess sub-visible particles in challenging formulations is warranted.
Collapse
Affiliation(s)
- Grant E. Frahm
- Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada
| | - Alex W. T. Pochopsky
- Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada
- University of Ottawa, Department of Biochemistry, Ottawa, Ontario, Canada
| | - Tessa M. Clarke
- Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada
- University of Ottawa, Department of Mechanical Engineering, Ottawa, Ontario, Canada
| | - Michael J. W. Johnston
- Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada
- * E-mail:
| |
Collapse
|
207
|
Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. Vaccine 2016; 33 Suppl 2:B55-9. [PMID: 26022570 DOI: 10.1016/j.vaccine.2015.03.058] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Accepted: 03/19/2015] [Indexed: 11/20/2022]
Abstract
Since the development of the first vaccine over 200 years ago, vaccines have saved millions of lives and have become the most cost-effective modern medical intervention. However, over 70 years ago, Freund recognized that the effectiveness of the vaccine-induced immune responses could be vastly improved via the co-delivery of inflammation-induced agents, giving birth to the adjuvant field. Since the first description of adjuvants, revolutionary discoveries, including the discovery of dendritic cells and pattern recognition receptors, that drive remarkably different biological profiles, have opened the landscape of opportunities for the development of novel adjuvants able to trigger a remarkably diverse inflammatory profiles, thereby qualitatively and quantitatively skewing adaptive immunity in a tailored manner against target pathogens. However, mounting data point to a critical role for pre-existing inflammation as a predictor of vaccine responsiveness. Thus, in this review we will discuss novel opportunities by which pre-existing inflammation may be modulated, skewed, or tuned via next-generation vaccine approaches to enhanced vaccine-induced immunity in the elderly, immunocompromised, or subjects with chronic diseases.
Collapse
|
208
|
Abstract
An immunologic adjuvant, which enhances the magnitude and quality of immune responses to vaccine antigens, has become an essential part of modern vaccine practice. Chemicals and biologicals have been typically used for this purpose, but there are an increasing number of studies that are being conducted on the vaccine adjuvant effect of laser light on the skin. Currently, four different types or classes of laser devices have been shown to systemically enhance immune responses to intradermal vaccination: ultra-short pulsed lasers, non-pulsed lasers, non-ablative fractional lasers and ablative fractional lasers. Aside from involving the application of laser light to the skin in a manner that minimizes discomfort and damage, each type of laser vaccine adjuvant involves emission parameters, modes of action and immunologic adjuvant effects that are quite distinct from each other. This review provides a summary of the four major classes of “laser vaccine adjuvant” and clarifies and resolves their characteristics as immunologic adjuvants. These aspects of each adjuvant’s properties will ultimately help define which laser would be most efficacious in delivering a specific clinical benefit with a specific vaccine.
Collapse
Affiliation(s)
- Satoshi Kashiwagi
- Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, 149 13th Street, Charlestown, Massachusetts, 02129, United States of America
| | - Timothy Brauns
- Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, 149 13th Street, Charlestown, Massachusetts, 02129, United States of America
| | - Mark C Poznansky
- Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, 149 13th Street, Charlestown, Massachusetts, 02129, United States of America
| |
Collapse
|
209
|
Kimber I, Carrillo JC. Oral exposure to mineral oils: Is there an association with immune perturbation and autoimmunity? Toxicology 2016; 344-346:19-25. [DOI: 10.1016/j.tox.2016.01.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Revised: 01/19/2016] [Accepted: 01/22/2016] [Indexed: 12/18/2022]
|
210
|
Gableh F, Saeidi M, Hemati S, Hamdi K, Soleimanjahi H, Gorji A, Ghaemi A. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine. J Biomed Sci 2016; 23:16. [PMID: 26811064 PMCID: PMC4727273 DOI: 10.1186/s12929-016-0238-3] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Accepted: 01/20/2016] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND DNA vaccines have emerged as an attractive approach for the generation of cytotoxic T lymphocytes (CTL). In our previous study, we found That Toll like receptor (TLR) ligands are promising candidates for the development of novel adjuvants for DNA vaccine. To improve the efficacy of DNA vaccine directed against human papillomavirus (HPV) tumors, we evaluated whether co-administration of a TLR4 ligand, monophosphoryl lipid A (MPL), and Natural Killer T Cell Ligand α-Galactosylceramide(α-GalCer) adjuvants with DNA vaccine would influence the anti-tumor efficacy of DNA vaccinations. METHODS We investigated the effectiveness of α-GalCer and MPL combination as an adjuvant with an HPV-16 E7 DNA vaccine to enhance antitumor immune responses. RESULTS By using adjuvant combination for a DNA vaccine, we found that the levels of lymphocyte proliferation, CTL activity, IFN- γ, IL-4 and IL-12 responses, and tumor protection against TC-1 cells were significantly increased compared to the DNA vaccine with individual adjuvants. In addition, inhibition of IL-18 signaling during vaccination decreased IFN-γ responses and tumor protection, and that this inhibition suggested stimulatory role of IL-18 in adjuvant effects of α-GalCer and MPL combination. CONCLUSION The strong adjuvanticity associated with α-GalCer/MPL combination may to be an important tool in the development of novel and strong cancer immunotherapy.
Collapse
Affiliation(s)
- Fateme Gableh
- Infectious Diseases Research Center, Department of Microbiology, Golestan University of Medical Sciences, POBox: 49175-1141, Gorgan, Iran
| | - Mohsen Saeidi
- Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
| | - Shaghayegh Hemati
- Guilan Science and Research Branch, Islamic Azad University, Rasht, Iran
| | - Kasra Hamdi
- Department of microbiology, Islamic Azad University, Shiraz branch, Shiraz, Iran
| | - Hoorieh Soleimanjahi
- Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
| | - Ali Gorji
- Shefa Neuroscience Research Center, Tehran, Iran.,Epilepsy Research Center, Institut für Physiologie I, Westfälische Wilhelms-Universität Münster, Robert-Koch-Strasse, Münster, Germany.,Klinik und Poliklinik für Neurochirurgie, Department of Neurology, Westfälische Wilhelms-Universität Münster, Münster, Germany
| | - Amir Ghaemi
- Infectious Diseases Research Center, Department of Microbiology, Golestan University of Medical Sciences, POBox: 49175-1141, Gorgan, Iran. .,Shefa Neuroscience Research Center, Tehran, Iran. .,Department of Virology, Pasteur Institute of Iran, Tehran, Iran.
| |
Collapse
|
211
|
Hussein WM, Liu TY, Maruthayanar P, Mukaida S, Moyle PM, Wells JW, Toth I, Skwarczynski M. Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines. Chem Sci 2016; 7:2308-2321. [PMID: 29910921 PMCID: PMC5977935 DOI: 10.1039/c5sc03859f] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Accepted: 12/28/2015] [Indexed: 11/30/2022] Open
Abstract
Conjugation of multiple peptides by their N-termini is a promising technique to produce branched multiantigenic vaccines.
Conjugation of multiple peptides by their N-termini is a promising technique to produce branched multiantigenic vaccines. We established a double conjugation strategy that combines a mercapto-acryloyl Michael addition and a copper-catalysed alkyne-azide 1,3-dipolar cycloaddition (CuAAC) reaction to synthesise self-adjuvanting branched multiantigenic vaccine candidates. These vaccine candidates aim to treat cervical cancer and include two HPV-16 derived epitopes and a novel self-adjuvanting moiety. This is the first report of mercapto-acryloyl conjugation applied to the hetero conjugation of two unprotected peptides by their N-termini followed by a CuAAC reaction to conjugate a novel synthetic lipoalkyne self-adjuvanting moiety. In vivo experiments showed that the most promising vaccine candidate completely eradicated tumours in 46% of the mice (6 out of 13 mice).
Collapse
Affiliation(s)
- Waleed M Hussein
- School of Chemistry and Molecular Biosciences , The University of Queensland , Brisbane , QLD 4072 , Australia . ;
| | - Tzu-Yu Liu
- School of Chemistry and Molecular Biosciences , The University of Queensland , Brisbane , QLD 4072 , Australia . ;
| | - Pirashanthini Maruthayanar
- The University of Queensland Diamantina Institute , The University of Queensland , Translational Research Institute , Brisbane , Australia
| | - Saori Mukaida
- School of Chemistry and Molecular Biosciences , The University of Queensland , Brisbane , QLD 4072 , Australia . ;
| | - Peter M Moyle
- School of Pharmacy , The University of Queensland , Brisbane , QLD 4102 , Australia
| | - James W Wells
- The University of Queensland Diamantina Institute , The University of Queensland , Translational Research Institute , Brisbane , Australia
| | - Istvan Toth
- School of Chemistry and Molecular Biosciences , The University of Queensland , Brisbane , QLD 4072 , Australia . ; .,School of Pharmacy , The University of Queensland , Brisbane , QLD 4102 , Australia.,Institute for Molecular Bioscience , The University of Queensland , Brisbane , QLD 4072 , Australia
| | - Mariusz Skwarczynski
- School of Chemistry and Molecular Biosciences , The University of Queensland , Brisbane , QLD 4072 , Australia . ;
| |
Collapse
|
212
|
Lee E, Jang HE, Kang YY, Kim J, Ahn JH, Mok H. Submicron-sized hydrogels incorporating cyclic dinucleotides for selective delivery and elevated cytokine release in macrophages. Acta Biomater 2016; 29:271-281. [PMID: 26485167 DOI: 10.1016/j.actbio.2015.10.025] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 09/25/2015] [Accepted: 10/16/2015] [Indexed: 12/20/2022]
Abstract
Despite the emerging evidences supporting the potential of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) as a vaccine adjuvant, few properly designed micro-/nanocarriers for the delivery of cyclic dinucleotides have been developed. In this study, we formulated cGAMP within linear polyethyleneimine (LPEI)/hyaluronic acid (HA) hydrogels via inverse water-in-oil (W/O) emulsion/crosslinking. Spherical and cationic LPEI/HA hydrogels (LH gels) with a size of 455.3±3.1nm and a surface charge of 48.7±3.7mV were selectively and efficiently delivered into phagocytic macrophage cells, which are one type of antigen-presenting cells (APCs), but not into non-phagocytic fibroblast cells. LH gels incorporating cGAMP (LH/cGAMP gels) elicited excellent induction of the cytokines interferon-β (IFN-β) and interleukin-6 (IL-6). In particular, the amount of IFN-β released by LH hydrogels was significantly increased by 2.5-fold compared to that released by conventional cationic liposomes, such as Lipofectamine. In addition, fabricated LH gels showed superior biocompatibility in phagocytic cell lines and primary bone marrow-derived macrophages (BMDMs). After intramuscular injection with ovalbumin into C57BL/6 mice, LH/cGAMP gels exhibited significantly elevated levels of anti-ovalbumin total IgG in serum and IFN-β mRNA in spleens. Thus, the newly designed cGAMP-incorporating hydrogels can serve as safe and potent adjuvants for vaccination and immunotherapy. STATEMENT OF SIGNIFICANCE Since cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) was first found as a second messenger of immune signaling in human systems in February 2013 (Science, 15, 826), several scientific studies have been reported related to the potential of cGAMP as a vaccine adjuvant or additive for immunotherapy. However, only naked cGAMP without carriers were studied via intramuscular or intranasal administration so far. In our study, we first investigated the feasibility of polymeric hydrogels incorporating cGAMP in terms of selective uptake into phagocytic antigen presenting cells (APCs), induction of cytokines, production of target antibodies, and biocompatibility for vaccination and immunotherapy in vitro and in vivo. Therefore, we believe this manuscript would be of great interest to the biomaterial communities especially who are studying immunotherapy.
Collapse
Affiliation(s)
- Eunjoo Lee
- Department of Bioscience and Biotechnology, Konkuk University, Seoul 143-701, Republic of Korea
| | - Hyo-Eun Jang
- Department of Bioscience and Biotechnology, Konkuk University, Seoul 143-701, Republic of Korea
| | - Yoon Young Kang
- Department of Bioscience and Biotechnology, Konkuk University, Seoul 143-701, Republic of Korea
| | - Jihyun Kim
- Department of Bioscience and Biotechnology, Konkuk University, Seoul 143-701, Republic of Korea
| | - Joong-Hoon Ahn
- Department of Bioscience and Biotechnology, Konkuk University, Seoul 143-701, Republic of Korea
| | - Hyejung Mok
- Department of Bioscience and Biotechnology, Konkuk University, Seoul 143-701, Republic of Korea.
| |
Collapse
|
213
|
Zhang L, Zeng Z, Hu C, Bellis SL, Yang W, Su Y, Zhang X, Wu Y. Controlled and targeted release of antigens by intelligent shell for improving applicability of oral vaccines. Biomaterials 2016; 77:307-19. [DOI: 10.1016/j.biomaterials.2015.11.009] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Accepted: 11/06/2015] [Indexed: 12/31/2022]
|
214
|
Nishida S, Sugiyama H. Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine. Methods Mol Biol 2016; 1467:221-232. [PMID: 27417973 DOI: 10.1007/978-1-4939-4023-3_19] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
There is much current excitement about the potential of cancer immunotherapy. WT1 is high on the National Cancer Institute's list of priority antigens for immune therapy. In this chapter we describe a protocol for a clinical trial using a WT1 peptide-based cancer vaccine.
Collapse
Affiliation(s)
- Sumiyuki Nishida
- Department of Respiratory Medicine, Allergy and Rheumatic Disease, Graduate School of Medicine, Osaka University, 2-2, Yamada-Oka, Suita-City, Osaka, 565-0871, Japan.
| | - Haruo Sugiyama
- Department of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Osaka, Japan
| |
Collapse
|
215
|
Vasquez AE, Manzo RA, Soto DA, Barrientos MJ, Maldonado AE, Mosqueira M, Avila A, Touma J, Bruce E, Harris PR, Venegas A. Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant. Hum Vaccin Immunother 2015; 11:776-88. [PMID: 25750999 PMCID: PMC4514328 DOI: 10.1080/21645515.2015.1011011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
The Neisseria meningitidis outer membrane protein PorA from a Chilean strain was purified as a recombinant protein. PorA mixed with AbISCO induced bactericidal antibodies against N. meningitidis in mice. When PorA was fused to the Helicobacter pylori HpaA antigen gene, the specific response against H. pylori protein increased. Splenocytes from PorA-immunized mice were stimulated with PorA, and an increase in the secretion of IL-4 was observed compared with that of IFN-γ. Moreover, in an immunoglobulin sub-typing analysis, a substantially higher IgG1 level was found compared with IgG2a levels, suggesting a Th2-type immune response. This study revealed a peculiar behavior of the purified recombinant PorA protein per se in the absence of AbISCO as an adjuvant. Therefore, the resistance of PorA to proteolytic enzymes, such as those in the gastrointestinal tract, was analyzed, because this is an important feature for an oral protein adjuvant. Finally, we found that PorA fused to the H. pylori HpaA antigen, when expressed in Lactococcus lactis and administered orally, could enhance the antibody response against the HpaA antigen approximately 3 fold. These observations strongly suggest that PorA behaves as an effective oral adjuvant.
Collapse
Affiliation(s)
- Abel E Vasquez
- a Department of Biotechnology ; Instituto de Salud Pública de Chile ; Ñuñoa , Santiago , Chile
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
216
|
Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2015; 23:137-47. [PMID: 26656121 DOI: 10.1128/cvi.00458-15] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Accepted: 12/04/2015] [Indexed: 11/20/2022]
Abstract
Mycobacterium tuberculosis HN878 represents a virulent clinical strain from the W-Beijing family, which has been tested in small animal models in order to study its virulence and its induction of host immune responses following infection. This isolate causes death and extensive lung pathology in infected C57BL/6 mice, whereas lab-adapted strains, such as M. tuberculosis H37Rv, do not. The use of this clinically relevant isolate of M. tuberculosis increases the possibilities of assessing the long-lived efficacy of tuberculosis vaccines in a relatively inexpensive small animal model. This model will also allow for the use of knockout mouse strains to critically examine key immunological factors responsible for long-lived, vaccine-induced immunity in addition to vaccine-mediated prevention of pulmonary immunopathology. In this study, we show that the ID93/glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) tuberculosis vaccine candidate, currently in human clinical trials, is able to elicit protection against M. tuberculosis HN878 by reducing the bacterial burden in the lung and spleen and by preventing the extensive lung pathology induced by this pathogen in C57BL/6 mice.
Collapse
|
217
|
The Adjuvant Activity of Epimedium Polysaccharide-Propolis Flavone Liposome on Enhancing Immune Responses to Inactivated Porcine Circovirus Vaccine in Mice. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2015; 2015:972083. [PMID: 26612996 PMCID: PMC4647051 DOI: 10.1155/2015/972083] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 10/01/2015] [Indexed: 12/30/2022]
Abstract
Objectives. The adjuvant activity of Epimedium polysaccharide-propolis flavone liposome (EPL) was investigated in vitro and in vivo. Methods. In vitro, the effects of EPL at different concentrations on splenic lymphocytes proliferation and mRNA expression of IFN-γ and IL-6 were determined. In vivo, the adjuvant activities of EPL, EP, and mineral oil were compared in BALB/c mice through vaccination with inactivated porcine circovirus type 2 (PCV2) vaccine. Results. In vitro, EPL promoted lymphocytes proliferation and increased the mRNA expression of IFN-γ and IL-6, and the effect was significantly better than EP at all concentrations. In vivo, EPL significantly promoted the lymphocytes proliferation and the secretion of cytokines and improved the killing activity of NK cells, PCV2-specific antibody titers, and the proportion of T-cell subgroups. The effects of EPL were significantly better than EP and oil adjuvant at most time points. Conclusion. EPL could significantly improve both PCV2-specific cellular and humoral immune responses, and its medium dose had the best efficacy. Therefore, EPL would be exploited in an effective immune adjuvant for inactivated PCV2 vaccine.
Collapse
|
218
|
Liu Y, Tian X, Jiang S, Ren X, Liu F, Yang J, Chen Y, Jiang Y. Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells. Cell Immunol 2015; 298:18-24. [DOI: 10.1016/j.cellimm.2015.08.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Revised: 08/09/2015] [Accepted: 08/17/2015] [Indexed: 12/25/2022]
|
219
|
Lababidi S, Sutherland A, Krasnicka B, Forshee RA, Anderson SA. Overall conceptual framework for studying the genetics of autoimmune diseases following vaccination: a regulatory perspective. Biomark Med 2015; 9:1107-20. [DOI: 10.2217/bmm.15.67] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
The US Vaccine Adverse Event Reporting System contains case reports of autoimmune diseases (ADs) occurring following vaccinations. ADs are rare and occur in unvaccinated people, making the potential association between vaccines and ADs challenging to evaluate. Developing mechanistic pathways that link genes, immune mediators, vaccine components and ADs would be helpful for hypothesis generation, enhancing theories of biologic plausibility and grouping rare autoimmune adverse events to increase the ability to detect and evaluate safety signals. Here, we propose a conceptual framework for investigating the genetics of ADs as safety signals following vaccination, potentially contributing to the identification of relevant biomarkers. We also discuss a study design that incorporates genetic information into postmarket clinical evaluation of autoimmune adverse events following vaccination.
Collapse
Affiliation(s)
- Samir Lababidi
- Office of Biostatistics & Epidemiology, Center for Biologics Evaluation & Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, USA
| | - Andrea Sutherland
- Johns Hopkins University, School of Public Health, Baltimore MD, USA
| | - Barbara Krasnicka
- Division of Biostatistics, Office of Biostatistics & Epidemiology, Center for Biologics Evaluation & Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, USA
| | - Richard A Forshee
- Office of Biostatistics & Epidemiology, Center for Biologics Evaluation & Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, USA
| | - Steven A Anderson
- Office of Biostatistics & Epidemiology, Center for Biologics Evaluation & Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, USA
| |
Collapse
|
220
|
Ibañez AE, Coria LM, Carabajal MV, Delpino MV, Risso GS, Cobiello PG, Rinaldi J, Barrionuevo P, Bruno L, Frank F, Klinke S, Goldbaum FA, Briones G, Giambartolomei GH, Pasquevich KA, Cassataro J. A bacterial protease inhibitor protects antigens delivered in oral vaccines from digestion while triggering specific mucosal immune responses. J Control Release 2015; 220:18-28. [PMID: 26456256 DOI: 10.1016/j.jconrel.2015.10.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 10/06/2015] [Indexed: 01/18/2023]
Abstract
We report here that a bacterial protease inhibitor from Brucella spp. called U-Omp19 behaves as an ideal constituent for a vaccine formulation against infectious diseases. When co-administered orally with an antigen (Ag), U-Omp19: i) can bypass the harsh environment of the gastrointestinal tract by inhibiting stomach and intestine proteases and consequently increases the half-life of the co-administered Ag at immune inductive sites: Peyer's patches and mesenteric lymph nodes while ii) it induces the recruitment and activation of antigen presenting cells (APCs) and increases the amount of intracellular Ag inside APCs. Therefore, mucosal as well as systemic Ag-specific immune responses, antibodies, Th1, Th17 and CD8(+) T cells are enhanced when U-Omp19 is co-administered with the Ag orally. Finally, this bacterial protease inhibitor in an oral vaccine formulation confers mucosal protection and reduces parasite loads after oral challenge with virulent Toxoplasma gondii.
Collapse
Affiliation(s)
- Andrés Esteban Ibañez
- Instituto de Investigaciones Biotecnológicas-"Dr. Rodolfo A. Ugalde" Instituto Tecnológico de Chascomús (IIB-INTECH), Universidad Nacional de San Martín (UNSAM) CONICET, San Martín, Buenos Aires, Argentina
| | - Lorena Mirta Coria
- Instituto de Investigaciones Biotecnológicas-"Dr. Rodolfo A. Ugalde" Instituto Tecnológico de Chascomús (IIB-INTECH), Universidad Nacional de San Martín (UNSAM) CONICET, San Martín, Buenos Aires, Argentina
| | - Marianela Verónica Carabajal
- Instituto de Investigaciones Biotecnológicas-"Dr. Rodolfo A. Ugalde" Instituto Tecnológico de Chascomús (IIB-INTECH), Universidad Nacional de San Martín (UNSAM) CONICET, San Martín, Buenos Aires, Argentina
| | - María Victoria Delpino
- Instituto de Inmunología, Genética y Metabolismo (INIGEM), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad de Buenos Aires (UBA) Laboratorio de Inmunogenética, Hospital de Clínicas "José de San Martín", Facultad de Medicina, UBA, Buenos Aires, Argentina
| | - Gabriela Sofía Risso
- Instituto de Investigaciones Biotecnológicas-"Dr. Rodolfo A. Ugalde" Instituto Tecnológico de Chascomús (IIB-INTECH), Universidad Nacional de San Martín (UNSAM) CONICET, San Martín, Buenos Aires, Argentina
| | - Paula Gonzalez Cobiello
- Instituto de Estudios de la Inmunidad Humoral (IDEHU), CONICET-UBA, Facultad de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina; Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, UBA, Buenos Aires, Argentina
| | - Jimena Rinaldi
- Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | - Paula Barrionuevo
- Instituto de Medicina Experimental (CONICET-Academia Nacional de Medicina), Buenos Aires, Argentina
| | - Laura Bruno
- Instituto de Investigaciones Biotecnológicas-"Dr. Rodolfo A. Ugalde" Instituto Tecnológico de Chascomús (IIB-INTECH), Universidad Nacional de San Martín (UNSAM) CONICET, San Martín, Buenos Aires, Argentina
| | - Fernanda Frank
- Instituto de Estudios de la Inmunidad Humoral (IDEHU), CONICET-UBA, Facultad de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina; Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, UBA, Buenos Aires, Argentina
| | - Sebastián Klinke
- Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | | | - Gabriel Briones
- Instituto de Investigaciones Biotecnológicas-"Dr. Rodolfo A. Ugalde" Instituto Tecnológico de Chascomús (IIB-INTECH), Universidad Nacional de San Martín (UNSAM) CONICET, San Martín, Buenos Aires, Argentina
| | - Guillermo Hernán Giambartolomei
- Instituto de Inmunología, Genética y Metabolismo (INIGEM), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad de Buenos Aires (UBA) Laboratorio de Inmunogenética, Hospital de Clínicas "José de San Martín", Facultad de Medicina, UBA, Buenos Aires, Argentina
| | - Karina Alejandra Pasquevich
- Instituto de Investigaciones Biotecnológicas-"Dr. Rodolfo A. Ugalde" Instituto Tecnológico de Chascomús (IIB-INTECH), Universidad Nacional de San Martín (UNSAM) CONICET, San Martín, Buenos Aires, Argentina
| | - Juliana Cassataro
- Instituto de Investigaciones Biotecnológicas-"Dr. Rodolfo A. Ugalde" Instituto Tecnológico de Chascomús (IIB-INTECH), Universidad Nacional de San Martín (UNSAM) CONICET, San Martín, Buenos Aires, Argentina.
| |
Collapse
|
221
|
Someabozorg MA, Mirkazemi S, Mehrizi AA, Shokri F, Djadid ND, Zakeri S. Administration of naloxone in combination with recombinant Plasmodium vivax AMA-1 in BALB/c mice induces mixed Th1/Th2 immune responses. Parasite Immunol 2015; 37:521-532. [PMID: 26234932 DOI: 10.1111/pim.12220] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2015] [Accepted: 07/28/2015] [Indexed: 11/30/2022]
Abstract
Naloxone (NLX) has the ability to shift the immune response to a Th1 profile. Therefore, the adjuvant efficacy of NLX with recombinant P. vivax apical membrane antigen-1(rPvAMA-1) in BALB/c mice was evaluated. Mice were immunized subcutaneously with purified rPvAMA-1 formulated with NLX (doses of 5 mg/kg body weight) alone or in combination with IFA. A significant increase in anti-PvAMA-1 IgG antibody after the second boost (mean OD490 = 2·08 and 2·17, in groups received, rPvAMA-1/NLX and rPvAMA-1/NLX/IFA, respectively) was detected. IgG1 and IgG2b were the predominant isotypes in all immunized mouse groups. In immunized mice with rPvAMA-1/NLX (mean: 1036 pg/mL) and with rPvAMA-1/NLX/IFA (mean: 1024 pg/mL), IFN-γ was elicited in response to rPvAMA-1 after the second boost. No detectable IL-4 secretion was determined in all tested groups. In conclusion, the administration of NLX alone or NLX/IFA with rPvAMA-1 in BALB/c mice, which induced mixed Th1/Th2 immune responses, was comparable with that of the same recombinant antigen with CFA/IFA adjuvant. The results indicate that NLX alone may possibly not be considered as a potent Th1 adjuvant in PvAMA-1-based vaccine. However, in order to modulate immune responses from mixed Th1/Th2 to strong and protective Th1 response, further study is warranted on combination of NLX with other adjuvants such as CpG motifs or MPL in proper vaccine formulation. Additionally, dose-response study is necessary to determine the effect of different doses of antigen combined with NLX (at various doses) in Balb/c mice.
Collapse
Affiliation(s)
- M A Someabozorg
- Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.,Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - S Mirkazemi
- Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran
| | - A A Mehrizi
- Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran
| | - F Shokri
- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - N D Djadid
- Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran
| | - S Zakeri
- Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
222
|
Gamazo C, Martín-Arbella N, Brotons A, Camacho AI, Irache JM. Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization. Eur J Pharm Biopharm 2015; 96:454-63. [PMID: 25615880 PMCID: PMC7126451 DOI: 10.1016/j.ejpb.2015.01.010] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Revised: 01/07/2015] [Accepted: 01/12/2015] [Indexed: 02/06/2023]
Abstract
Dealing with mucosal delivery systems means dealing with mucus. The name mucosa comes from mucus, a dense fluid enriched in glycoproteins, such as mucin, which main function is to protect the delicate mucosal epithelium. Mucus provides a barrier against physiological chemical and physical aggressors (i.e., host secreted digestive products such as bile acids and enzymes, food particles) but also against the potentially noxious microbiota and their products. Intestinal mucosa covers 400m(2) in the human host, and, as a consequence, is the major portal of entry of the majority of known pathogens. But, in turn, some microorganisms have evolved many different approaches to circumvent this barrier, a direct consequence of natural co-evolution. The understanding of these mechanisms (known as virulence factors) used to interact and/or disrupt mucosal barriers should instruct us to a rational design of nanoparticulate delivery systems intended for oral vaccination and immunotherapy. This review deals with this mimetic approach to obtain nanocarriers capable to reach the epithelial cells after oral delivery and, in parallel, induce strong and long-lasting immune and protective responses.
Collapse
Affiliation(s)
- Carlos Gamazo
- Department of Microbiology, University of Navarra, Pamplona, Spain
| | - Nekane Martín-Arbella
- Department of Pharmacy and Pharmaceutical Technology, University of Navarra, Pamplona, Spain
| | - Ana Brotons
- Department of Pharmacy and Pharmaceutical Technology, University of Navarra, Pamplona, Spain
| | - Ana I Camacho
- Department of Microbiology, University of Navarra, Pamplona, Spain
| | - J M Irache
- Department of Pharmacy and Pharmaceutical Technology, University of Navarra, Pamplona, Spain.
| |
Collapse
|
223
|
Bi J, Yang F, Harbottle D, Pensini E, Tchoukov P, Simon S, Sjöblom J, Dabros T, Czarnecki J, Liu Q, Xu Z. Interfacial Layer Properties of a Polyaromatic Compound and its Role in Stabilizing Water-in-Oil Emulsions. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2015; 31:10382-10391. [PMID: 26325243 DOI: 10.1021/acs.langmuir.5b02177] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Physical properties of interfacial layers formed at the xylene-water interface by the adsorption of a polyaromatic organic compound, N-(1-hexylheptyl)-N'-(5-carbonylicpentyl) perylene-3,4,9,10-tetracarboxylic bisimide (in brief, C5Pe), were studied systematically. The deprotonation of the carboxylic group of C5Pe at alkaline pH made it highly interfacially active, significantly reducing the xylene-water interfacial tension. Thin liquid film experiments showed a continuous buildup of heterogeneous C5Pe interfacial layers at the xylene-water interfaces, which contributed to the formation of stable W/O emulsions. Continual accumulation and rearrangement of C5Pe aggregates at the xylene-water interface to form a thick layer was confirmed by in situ Brewster angle microscopy (BAM) and atomic force microscopy (AFM). The rheology measurement of the interfacial layer by double-wall ring interfacial rheometry under oscillatory shear showed that the interfacial layers formed from C5Pe solutions of high concentrations were substantially more elastic and rigid. The presence of elastically dominant interfacial layers of C5Pe led to the formation of stable water-in-xylene emulsions.
Collapse
Affiliation(s)
- Jiebin Bi
- Department of Chemical and Materials Engineering, University of Alberta , Edmonton, Alberta, Canada
| | - Fan Yang
- Department of Chemical and Materials Engineering, University of Alberta , Edmonton, Alberta, Canada
| | - David Harbottle
- Department of Chemical and Materials Engineering, University of Alberta , Edmonton, Alberta, Canada
- School of Chemical and Process Engineering, University of Leeds , Leeds, U.K
| | - Erica Pensini
- Department of Chemical and Materials Engineering, University of Alberta , Edmonton, Alberta, Canada
| | - Plamen Tchoukov
- Department of Chemical and Materials Engineering, University of Alberta , Edmonton, Alberta, Canada
| | - Sébastien Simon
- Ugelstad Laboratory, Department of Chemical Engineering, Norwegian University of Sciences and Technology (NTNU) , Trondheim, Norway
| | - Johan Sjöblom
- Ugelstad Laboratory, Department of Chemical Engineering, Norwegian University of Sciences and Technology (NTNU) , Trondheim, Norway
| | - Tadek Dabros
- CanmetENERGY, Natural Resources Canada, Devon, Alberta, Canada
| | - Jan Czarnecki
- Department of Chemical and Materials Engineering, University of Alberta , Edmonton, Alberta, Canada
| | - Qingxia Liu
- Department of Chemical and Materials Engineering, University of Alberta , Edmonton, Alberta, Canada
| | - Zhenghe Xu
- Department of Chemical and Materials Engineering, University of Alberta , Edmonton, Alberta, Canada
| |
Collapse
|
224
|
Wang X, Li X, Ito A, Watanabe Y, Sogo Y, Tsuji NM, Ohno T. Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201506179] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Xiupeng Wang
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Xia Li
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Atsuo Ito
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Yohei Watanabe
- Biomedical Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Yu Sogo
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Noriko M. Tsuji
- Biomedical Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Tadao Ohno
- School of Life Dentistry at Tokyo; The Nippon Dental University; Fujimi Chiyoda-ku Tokyo 102-0071 Japan
| |
Collapse
|
225
|
Wang X, Li X, Ito A, Watanabe Y, Sogo Y, Tsuji NM, Ohno T. Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres. Angew Chem Int Ed Engl 2015; 55:1899-903. [DOI: 10.1002/anie.201506179] [Citation(s) in RCA: 100] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Revised: 08/25/2015] [Indexed: 11/09/2022]
Affiliation(s)
- Xiupeng Wang
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Xia Li
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Atsuo Ito
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Yohei Watanabe
- Biomedical Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Yu Sogo
- Health Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Noriko M. Tsuji
- Biomedical Research Institute, Department of Life Science and Biotechnology; National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi Tsukuba Ibaraki 305-8566 Japan
| | - Tadao Ohno
- School of Life Dentistry at Tokyo; The Nippon Dental University; Fujimi Chiyoda-ku Tokyo 102-0071 Japan
| |
Collapse
|
226
|
Comparative Analysis of the Molecular Adjuvants and Their Binding Efficiency with CR1. Interdiscip Sci 2015; 8:35-40. [PMID: 26264056 DOI: 10.1007/s12539-015-0279-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Revised: 01/16/2015] [Accepted: 01/16/2015] [Indexed: 12/20/2022]
Abstract
There are so many obstacles in developing a vaccine or vaccine technology for diseases like cancer and human immunodeficiency virus infection. While developing vaccines that target specific infection, molecular adjuvants are indispensable. These molecular adjuvants act as a vaccine delivery vehicle to the immune system to increase the effectiveness of the specific antigens. In the present work, a computational study has been done on molecular adjuvants like IgGFc, GMCSF and C3d to find out how efficiently they are binding to CR1. Sequence, structure and mutational analysis are performed on the molecular adjuvants to understand the features important for their binding with the receptor. Results obtained from our study indicate that the adjuvant IgGFc complexed with the receptor CR1 has the best binding efficiency, which can be used further to develop better vaccine technologies.
Collapse
|
227
|
Small Wonders-The Use of Nanoparticles for Delivering Antigen. Vaccines (Basel) 2015; 3:638-61. [PMID: 26350599 PMCID: PMC4586471 DOI: 10.3390/vaccines3030638] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 07/15/2015] [Accepted: 07/31/2015] [Indexed: 12/19/2022] Open
Abstract
Despite the discovery of many potential antigens for subunit vaccines, universal protection is often lacking due to the limitations of conventional delivery methods. Subunit vaccines primarily induce antibody-mediated humoral responses, whereas potent antigen-specific cellular responses are required for prevention against some pathogenic infections. Nanoparticles have been utilised in nanomedicine and are promising candidates for vaccine or drug delivery. Nanoparticle vehicles have been demonstrated to be efficiently taken up by dendritic cells and induce humoral and cellular responses. This review provides an overview of nanoparticle vaccine development; in particular, the preparation of nanoparticles using a templating technique is highlighted, which would alleviate some of the disadvantages of existing nanoparticles. We will also explore the cellular fate of nanoparticle vaccines. Nanoparticle-based antigen delivery systems have the potential to develop new generation vaccines against currently unpreventable infectious diseases.
Collapse
|
228
|
Chitosan-based mucosal adjuvants: Sunrise on the ocean. Vaccine 2015; 33:5997-6010. [PMID: 26271831 PMCID: PMC7185844 DOI: 10.1016/j.vaccine.2015.07.101] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 07/22/2015] [Accepted: 07/28/2015] [Indexed: 12/20/2022]
Abstract
Metabolism and safety profile of chitosan and its derivatives on mucosal application. Mechanisms of chitosan as potent mucosal adjuvant. Different types and forms of chitosan in pre-clinical applications. Clinical perspectives.
Mucosal vaccination, which is shown to elicit systemic and mucosal immune responses, serves as a non-invasive and convenient alternative to parenteral administration, with stronger capability in combatting diseases at the site of entry. The exploration of potent mucosal adjuvants is emerging as a significant area, based on the continued necessity to amplify the immune responses to a wide array of antigens that are poorly immunogenic at the mucosal sites. As one of the inspirations from the ocean, chitosan-based mucosal adjuvants have been developed with unique advantages, such as, ability of mucosal adhesion, distinct trait of opening the junctions to allow the paracellular transport of antigen, good tolerability and biocompatibility, which guaranteed the great potential in capitalizing on their application in human clinical trials. In this review, the state of art of chitosan and its derivatives as mucosal adjuvants, including thermo-sensitive chitosan system as mucosal adjuvant that were newly developed by author's group, was described, as well as the clinical application perspective. After a brief introduction of mucosal adjuvants, chitosan and its derivatives as robust immune potentiator were discussed in detail and depth, in regard to the metabolism, safety profile, mode of actions and preclinical and clinical applications, which may shed light on the massive clinical application of chitosan as mucosal adjuvant.
Collapse
|
229
|
Kashiwagi S, Brauns T, Gelfand J, Poznansky MC. Laser vaccine adjuvants. History, progress, and potential. Hum Vaccin Immunother 2015; 10:1892-907. [PMID: 25424797 DOI: 10.4161/hv.28840] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Immunologic adjuvants are essential for current vaccines to maximize their efficacy. Unfortunately, few have been found to be sufficiently effective and safe for regulatory authorities to permit their use in vaccines for humans and none have been approved for use with intradermal vaccines. The development of new adjuvants with the potential to be both efficacious and safe constitutes a significant need in modern vaccine practice. The use of non-damaging laser light represents a markedly different approach to enhancing immune responses to a vaccine antigen, particularly with intradermal vaccination. This approach, which was initially explored in Russia and further developed in the US, appears to significantly improve responses to both prophylactic and therapeutic vaccines administered to the laser-exposed tissue, particularly the skin. Although different types of lasers have been used for this purpose and the precise molecular mechanism(s) of action remain unknown, several approaches appear to modulate dendritic cell trafficking and/or activation at the irradiation site via the release of specific signaling molecules from epithelial cells. The most recent study, performed by the authors of this review, utilized a continuous wave near-infrared laser that may open the path for the development of a safe, effective, low-cost, simple-to-use laser vaccine adjuvant that could be used in lieu of conventional adjuvants, particularly with intradermal vaccines. In this review, we summarize the initial Russian studies that have given rise to this approach and comment upon recent advances in the use of non-tissue damaging lasers as novel physical adjuvants for vaccines.
Collapse
Affiliation(s)
- Satoshi Kashiwagi
- a Vaccine and Immunotherapy Center; Division of Infectious Diseases; Department of Medicine, Massachusetts General Hospital; Charlestown, MA USA
| | | | | | | |
Collapse
|
230
|
Salazar-González JA, González-Ortega O, Rosales-Mendoza S. Gold nanoparticles and vaccine development. Expert Rev Vaccines 2015; 14:1197-211. [DOI: 10.1586/14760584.2015.1064772] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- Jorge Alberto Salazar-González
- Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP, 78210, México
| | - Omar González-Ortega
- Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP, 78210, México
| | | |
Collapse
|
231
|
Cordeiro AS, Alonso MJ, de la Fuente M. Nanoengineering of vaccines using natural polysaccharides. Biotechnol Adv 2015; 33:1279-93. [PMID: 26049133 PMCID: PMC7127432 DOI: 10.1016/j.biotechadv.2015.05.010] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Revised: 05/29/2015] [Accepted: 05/31/2015] [Indexed: 12/14/2022]
Abstract
Currently, there are over 70 licensed vaccines, which prevent the pathogenesis of around 30 viruses and bacteria. Nevertheless, there are still important challenges in this area, which include the development of more active, non-invasive, and thermo-resistant vaccines. Important biotechnological advances have led to safer subunit antigens, such as proteins, peptides, and nucleic acids. However, their limited immunogenicity has demanded potent adjuvants that can strengthen the immune response. Particulate nanocarriers hold a high potential as adjuvants in vaccination. Due to their pathogen-like size and structure, they can enhance immune responses by mimicking the natural infection process. Additionally, they can be tailored for non-invasive mucosal administration (needle-free vaccination), and control the delivery of the associated antigens to a specific location and for prolonged times, opening room for single-dose vaccination. Moreover, they allow co-association of immunostimulatory molecules to improve the overall adjuvant capacity. The natural and ubiquitous character of polysaccharides, together with their intrinsic immunomodulating properties, their biocompatibility, and biodegradability, justify their interest in the engineering of nanovaccines. In this review, we aim to provide a state-of-the-art overview regarding the application of nanotechnology in vaccine delivery, with a focus on the most recent advances in the development and application of polysaccharide-based antigen nanocarriers.
Collapse
Affiliation(s)
- Ana Sara Cordeiro
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Health Research Institute of Santiago de Compostela (IDIS), School of Pharmacy, University of Santiago de Compostela, Campus Vida, 15706 Santiago de Compostela, Spain; Nano-oncologicals Lab, Translational Medical Oncology group, Health Research Institute of Santiago de Compostela (IDIS), University Hospital Complex of Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
| | - María José Alonso
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Health Research Institute of Santiago de Compostela (IDIS), School of Pharmacy, University of Santiago de Compostela, Campus Vida, 15706 Santiago de Compostela, Spain
| | - María de la Fuente
- Nano-oncologicals Lab, Translational Medical Oncology group, Health Research Institute of Santiago de Compostela (IDIS), University Hospital Complex of Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain.
| |
Collapse
|
232
|
Wang S, Liu H, Zhang X, Qian F. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell 2015; 6:480-503. [PMID: 25944045 PMCID: PMC4491048 DOI: 10.1007/s13238-015-0164-2] [Citation(s) in RCA: 97] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Accepted: 04/10/2015] [Indexed: 02/06/2023] Open
Abstract
Most pathogens initiate their infections at the human mucosal surface. Therefore, mucosal vaccination, especially through oral or intranasal administration routes, is highly desired for infectious diseases. Meanwhile, protein-based antigens provide a safer alternative to the whole pathogen or DNA based ones in vaccine development. However, the unique biopharmaceutical hurdles that intranasally or orally delivered protein vaccines need to overcome before they reach the sites of targeting, the relatively low immunogenicity, as well as the low stability of the protein antigens, require thoughtful and fine-tuned mucosal vaccine formulations, including the selection of immunostimulants, the identification of the suitable vaccine delivery system, and the determination of the exact composition and manufacturing conditions. This review aims to provide an up-to-date survey of the protein antigen-based vaccine formulation development, including the usage of immunostimulants and the optimization of vaccine delivery systems for intranasal and oral administrations.
Collapse
Affiliation(s)
- Shujing Wang
- Department of Pharmacology and Pharmaceutical Sciences, School of Medicine and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Tsinghua University, Beijing, 100084, China
| | | | | | | |
Collapse
|
233
|
Abkar M, Amani J, Sahebghadam Lotfi A, Nikbakht Brujeni G, Alamian S, Kamali M. Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection againstBrucella abortusandBrucella melitensisinfections. APMIS 2015; 123:667-75. [DOI: 10.1111/apm.12400] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2014] [Accepted: 04/09/2015] [Indexed: 02/03/2023]
Affiliation(s)
- Morteza Abkar
- Department of Molecular Genetics; Faculty of Basic Sciences; Tarbiat Modares University; Tehran Iran
| | - Jafar Amani
- Applied Microbiology Research Center; Baqiyatallah University of Medical Sciences; Tehran Iran
| | - Abbas Sahebghadam Lotfi
- Department of Clinical Biochemistry; Faculty of Medicine; Tarbiat Modares University; Tehran Iran
| | - Gholamreza Nikbakht Brujeni
- Department of Microbiology and Immunology; Faculty of Veterinary Medicine; University of Tehran; Tehran Iran
| | - Saeed Alamian
- Brucellosis Department; Razi Vaccine and Serum Research Institute; Karaj Iran
| | - Mehdi Kamali
- Nanobiotechnology Research Center; Baqiyatallah University of Medical Sciences; Tehran Iran
| |
Collapse
|
234
|
Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw 2015; 15:51-7. [PMID: 25922593 PMCID: PMC4411509 DOI: 10.4110/in.2015.15.2.51] [Citation(s) in RCA: 265] [Impact Index Per Article: 29.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 03/28/2015] [Accepted: 04/02/2015] [Indexed: 12/12/2022] Open
Abstract
Vaccines are the most effective and cost-efficient method for preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe and strong vaccines is still required for emerging new pathogens, re-emerging old pathogens, and in order to improve the inadequate protection conferred by existing vaccines. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing vaccine potency by improvement of the humoral and/or cell-mediated immune response to vaccine antigens. Thus, formulation of vaccines with appropriate adjuvants is an attractive approach towards eliciting protective and long-lasting immunity in humans. However, only a limited number of adjuvants is licensed for human vaccines due to concerns about safety and toxicity. We summarize current knowledge about the potential benefits of adjuvants, the characteristics of adjuvants and the mechanisms of adjuvants in human vaccines. Adjuvants have diverse modes of action and should be selected for use on the basis of the type of immune response that is desired for a particular vaccine. Better understanding of current adjuvants will help exploring new adjuvant formulations and facilitate rational design of vaccines against infectious diseases.
Collapse
Affiliation(s)
- Sujin Lee
- Department of Pediatrics, Emory University, School of Medicine, Atlanta, Georgia 30322, USA. ; Children's Healthcare of Atlanta, Atlanta, Georgia 30322, USA
| | - Minh Trang Nguyen
- Department of Pediatrics, Emory University, School of Medicine, Atlanta, Georgia 30322, USA. ; Children's Healthcare of Atlanta, Atlanta, Georgia 30322, USA
| |
Collapse
|
235
|
The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. SPRINGERPLUS 2015; 4:181. [PMID: 25932368 PMCID: PMC4406982 DOI: 10.1186/s40064-015-0972-0] [Citation(s) in RCA: 99] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Accepted: 04/08/2015] [Indexed: 12/23/2022]
Abstract
Adjuvants such as the aluminum compounds (alum) have been dominantly used in many vaccines due to their immunopotentiation and safety records since 1920s. However, how these mineral agents influence the immune response to vaccination remains elusive. Many hypotheses exist as to the mode of action of these adjuvants, such as depot formation, antigen (Ag) targeting, and the induction of inflammation. These hypotheses are based on many in vitro and few in vivo studies. Understanding how cells interact with adjuvants in vivo will be crucial to fully understanding the mechanisms of action of these adjuvants. Interestingly, how alum influences the target cell at both the cellular and molecular level, and the consequent innate and adaptive responses, will be critical in the rational design of effective vaccines against many diseases. Thus, in this review, mechanisms of action of alum have been discussed based on available in vitro vs in vivo evidences to date.
Collapse
|
236
|
Kim DK, Won KH, Moon SH, Lee HK. Identification of Molecular Signatures from Different Vaccine Adjuvants in Chicken by Integrative Analysis of Microarray Data. ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES 2015; 29:1044-51. [PMID: 26954188 PMCID: PMC4932582 DOI: 10.5713/ajas.14.0923] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 01/09/2015] [Accepted: 02/11/2015] [Indexed: 11/27/2022]
Abstract
The present study compared the differential functions of two groups of adjuvants, Montanide incomplete Seppic adjuvant (ISA) series and Quil A, cholesterol, dimethyl dioctadecyl ammonium bromide, and Carbopol (QCDC) formulations, in chicken by analyzing published microarray data associated with each type of vaccine adjuvants. In the biological function analysis for differentially expressed genes altered by two different adjuvant groups, ISA series and QCDC formulations showed differential effects when chickens were immunized with a recombinant immunogenic protein of Eimeria. Among the biological functions, six categories were modified in both adjuvant types. However, with respect to “Response to stimulus”, no biological process was modified by the two adjuvant groups at the same time. The QCDC adjuvants showed effects on the biological processes (BPs) including the innate immune response and the immune response to the external stimulus such as toxin and bacterium, while the ISA adjuvants modified the BPs to regulate cell movement and the response to stress. In pathway analysis, ISA adjuvants altered the genes involved in the functions related with cell junctions and the elimination of exogenous and endogenous macromolecules. The analysis in the present study could contribute to the development of precise adjuvants based on molecular signatures related with their immunological functions.
Collapse
Affiliation(s)
| | - Kyeong Hye Won
- Department of Animal Biotechnology, Chonbuk National University, Jeonju 561-756, Korea
| | - Seung Hyun Moon
- Department of Animal Biotechnology, Chonbuk National University, Jeonju 561-756, Korea
| | - Hak-Kyo Lee
- Department of Animal Biotechnology, Chonbuk National University, Jeonju 561-756, Korea
| |
Collapse
|
237
|
Induction of potent adaptive immunity by the novel polyion complex nanoparticles. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2015; 22:578-85. [PMID: 25809631 DOI: 10.1128/cvi.00080-15] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 03/19/2015] [Indexed: 02/06/2023]
Abstract
The development of effective and simple methods of vaccine preparation is desired for the prophylaxis and treatment of a variety of infectious diseases and cancers. We have created novel polyion complex (PIC) nanoparticles (NPs) composed of amphiphilic anionic biodegradable poly(γ-glutamic acid) (γ-PGA) and cationic polymers as a vaccine adjuvant. PIC NPs can be prepared by mixing γ-PGA-graft-l-phenylalanine ethylester (γ-PGA-Phe) polymer with cationic polymer in phosphate-buffered saline. We examined the efficacy of PIC NPs for antigen delivery and immunostimulatory activity in vitro and in vivo. PIC NPs enhanced the uptake of ovalbumin (OVA) by dendritic cells (DCs) and subsequently induced DC maturation. The immunization of mice with OVA-carrying PIC NPs induced potent and antigen-specific cellular and humoral immunity. Since PIC NPs can be created with water-soluble anionic γ-PGA-Phe and a cationic polymer by simple mixing in the absence of any organic solvents, PIC NPs may have potential as a novel candidate for an effective antigen carrier and vaccine adjuvant.
Collapse
|
238
|
Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease. Vaccine 2015; 33:1274-83. [DOI: 10.1016/j.vaccine.2015.01.044] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Revised: 12/19/2014] [Accepted: 01/14/2015] [Indexed: 12/12/2022]
|
239
|
Tahoun A, Jensen K, Corripio-Miyar Y, McAteer SP, Corbishley A, Mahajan A, Brown H, Frew D, Aumeunier A, Smith DGE, McNeilly TN, Glass EJ, Gally DL. Functional analysis of bovine TLR5 and association with IgA responses of cattle following systemic immunisation with H7 flagella. Vet Res 2015; 46:9. [PMID: 25827709 PMCID: PMC4333180 DOI: 10.1186/s13567-014-0135-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2014] [Accepted: 12/11/2014] [Indexed: 11/14/2022] Open
Abstract
Flagellin subunits are important inducers of host immune responses through activation of TLR5 when extracellular and the inflammasome if cytosolic. Our previous work demonstrated that systemic immunization of cattle with flagella generates systemic and mucosal IgA responses. The IgA response in mice is TLR5-dependent and TLR5 can impact on the general magnitude of the adaptive response. However, due to sequence differences between bovine and human/murine TLR5 sequences, it is not clear whether bovine TLR5 (bTLR5) is able to stimulate an inflammatory response following interaction with flagellin. To address this we have examined the innate responses of both human and bovine cells containing bTLR5 to H7 flagellin from E. coli O157:H7. Both HEK293 (human origin) and embryonic bovine lung (EBL) cells transfected with bTLR5 responded to addition of H7 flagellin compared to non-transfected controls. Responses were significantly reduced when mutations were introduced into the TLR5-binding regions of H7 flagellin, including an R90T substitution. In bovine primary macrophages, flagellin-stimulated CXCL8 mRNA and secreted protein levels were significantly reduced when TLR5 transcript levels were suppressed by specific siRNAs and stimulation was reduced with the R90T-H7 variant. While these results indicate that the bTLR5 sequence produces a functional flagellin-recognition receptor, cattle immunized with R90T-H7 flagella also demonstrated systemic IgA responses to the flagellin in comparison to adjuvant only controls. This presumably either reflects our findings that R90T-H7 still activates bTLR5, albeit with reduced efficiency compared to WT H7 flagellin, or that other flagellin recognition pathways may play a role in this mucosal response.
Collapse
|
240
|
Saranya B, Saxena S, Saravanan KM, Shakila H. Comparative analysis of the molecular adjuvants and their binding efficiency with CR1. Interdiscip Sci 2015. [PMID: 25682380 DOI: 10.1007/s12539-014-0247-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Revised: 01/16/2015] [Accepted: 01/16/2015] [Indexed: 06/04/2023]
Abstract
There are so many obstacles in developing a vaccine or vaccine technology for diseases like Cancer and Human Immunodeficiency Virus (HIV) infection. While developing vaccines that targets specific infection, molecular adjuvants are indispensable. These molecular adjuvants act as a vaccine delivery vehicle to the immune system to increase the effectiveness of the specific antigens. In the present work, a computational study has been done on molecular adjuvants like IgGFc, GMCSF and C3d to find out how efficiently they are binding to CR1. Sequence, structure and mutational analysis are performed on the molecular adjuvants to understand the features important for their binding with the receptor. Results obtained from our study indicate that the adjuvant IgGFc complexed with the receptor CR1 has the best binding efficiency, which can be used further to develop better vaccine technologies.
Collapse
Affiliation(s)
- B Saranya
- Centre of Excellence in Bioinformatics School of Biotechnology Madurai Kamaraj University, Madurai, 625 021, Tamilnadu, India
| | | | | | | |
Collapse
|
241
|
Zeng Q, Jiang H, Wang T, Zhang Z, Gong T, Sun X. Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses. J Control Release 2015; 200:1-12. [DOI: 10.1016/j.jconrel.2014.12.024] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Revised: 12/03/2014] [Accepted: 12/17/2014] [Indexed: 12/11/2022]
|
242
|
Lim YT. Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease. Clin Exp Vaccine Res 2015; 4:54-8. [PMID: 25648865 PMCID: PMC4313109 DOI: 10.7774/cevr.2015.4.1.54] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 12/28/2014] [Accepted: 12/31/2014] [Indexed: 12/17/2022] Open
Abstract
Adjuvants can be defined as pharmacological and immunological components that are able to modify and/or enhance antigen-specific immune responses. Based on the interdisciplinary research between immunology and material science/engineering, various vaccine adjuvant materials have been developed. By rational design and engineering of antigen or adjuvant materials, immune-modulatory vaccine systems generated to activate immune system. Here, we review the current progress of bioengineered prophylactic and/or therapeutic vaccine adjuvant for cancer and/or infectious disease, and discuss the prospect of future vaccine adjuvant materials.
Collapse
Affiliation(s)
- Yong Taik Lim
- SKKU Advanced Institute of Nanotechnology, School of Chemical Engineering, Sungkyunkwan University, Suwon, Korea
| |
Collapse
|
243
|
Kallerup RS, Foged C. Classification of Vaccines. ADVANCES IN DELIVERY SCIENCE AND TECHNOLOGY 2015. [DOI: 10.1007/978-1-4939-1417-3_2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
244
|
Liu TY, Hussein WM, Giddam AK, Jia Z, Reiman JM, Zaman M, McMillan NAJ, Good MF, Monteiro MJ, Toth I, Skwarczynski M. Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine. J Med Chem 2014; 58:888-96. [PMID: 25489968 DOI: 10.1021/jm501514h] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Vaccination can provide a safe alternative to chemotherapy by using the body's natural defense mechanisms to create a potent immune response against tumor cells. Peptide-based therapeutic vaccines against human papillomavirus (HPV)-related cancers are usually designed to elicit cytotoxic T cell responses by targeting the HPV-16 E7 oncoprotein. However, peptides alone lack immunogenicity, and an additional adjuvant or external delivery system is required. In this study, we developed new polymer-peptide conjugates to create an efficient self-adjuvanting system for peptide-based therapeutic vaccines. These conjugates reduced tumor growth and eradicated E7-positive TC-1 tumors in mice after a "single shot" immunization, without the help from an external adjuvant. The new conjugates had a significantly higher anticancer efficacy than the antigen formulated with a commercial adjuvant. Furthermore, the polymer-peptide conjugates were promptly taken up by antigen presenting cells, including dendritic cells and macrophages, and efficiently activated CD4(+) T-helper cells and CD8(+) cytotoxic T lymphocyte cells.
Collapse
Affiliation(s)
- Tzu-Yu Liu
- School of Chemistry and Molecular Biosciences, ‡Australian Institute for Bioengineering and Nanotechnology, and §School of Pharmacy, The University of Queensland , Brisbane, QLD 4072, Australia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
245
|
Bayih AG, Daifalla NS, Gedamu L. DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant. PLoS Negl Trop Dis 2014; 8:e3391. [PMID: 25500571 PMCID: PMC4263403 DOI: 10.1371/journal.pntd.0003391] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2014] [Accepted: 10/31/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND To date, no universally effective and safe vaccine has been developed for general human use. Leishmania donovani Peroxidoxin-1 (LdPxn-1) is a member of the antioxidant family of proteins and is predominantly expressed in the amastigote stage of the parasite. The aim of this study was to evaluate the immunogenicity and protective efficacy of LdPxn-1 in BALB/c mice in heterologous DNA-Protein immunization regimen in the presence of fusion murine granulocyte-macrophage colony-stimulating factor (mGMCSF) DNA adjuvant. METHODOLOGY AND PRINCIPAL FINDINGS A fusion DNA of LdPxn1 and mGMCSF was cloned into a modified pcDNA vector. To confirm the expression in mammalian system, Chinese hamster ovary cells were transfected with the plasmid vector containing LdPxn1 gene. BALB/c mice were immunized twice with pcDNA-mGMCSF-LdPxn-1 or pcDNA-LdPxn1 DNA and boosted once with recombinant LdPxn-1 protein. Three weeks after the last immunization, mice were infected with Leishmania major promastigotes. The result showed that immunization with pcDNA-mGMCSF-LdPxn1 elicited a mixed Th-1/Th-2 immune response with significantly higher production of IFN-γ than controls. Intracellular cytokine staining of antigen-stimulated spleen cells showed that immunization with this antigen elicited significantly higher proportion of CD4+ T cells that express IFN-γ, TNF-α, or IL-2. The antigen also induced significantly higher proportion of multipotent CD4+ cells that simultaneously express the three Th-1 cytokines. Moreover, a significant reduction in the footpad swelling was seen in mice immunized with pcDNA-mGMCSF-LdPxn1 antigen. Expression study in CHO cells demonstrated that pcDNA-mGMCSF-LdPxn-1 was expressed in mammalian system. CONCLUSION The result demonstrates that immunization of BALB/c mice with a plasmid expressing LdPxn1 in the presence of mGMCSF adjuvant elicits a strong specific immune response with high level induction of multipotent CD4+ cells that mediate protection of the mice from Leishmania major infection. To our knowledge, this is the first study showing the vaccine potential of Leishmania peroxidoxin -1.
Collapse
Affiliation(s)
- Abebe Genetu Bayih
- Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada
- * E-mail:
| | - Nada S. Daifalla
- Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Lashitew Gedamu
- Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
246
|
Ma F, Zhang Q, Zheng L. Interleukin/chitosan (JY) adjuvant enhances the mucosal immunity of human papillomavirus 16 L1 virus-like particles in mice. Biotechnol Lett 2014; 37:773-7. [DOI: 10.1007/s10529-014-1739-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Accepted: 11/24/2014] [Indexed: 11/29/2022]
Affiliation(s)
- Fenlian Ma
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Yingxin Street 100, Beijing, 100052, China,
| | | | | |
Collapse
|
247
|
Polycation-decorated PLA microspheres induce robust immune responses via commonly used parenteral administration routes. Int Immunopharmacol 2014; 23:592-602. [DOI: 10.1016/j.intimp.2014.10.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Revised: 09/29/2014] [Accepted: 10/14/2014] [Indexed: 11/21/2022]
|
248
|
Mody KT, Mahony D, Zhang J, Cavallaro AS, Zhang B, Popat A, Mahony TJ, Yu C, Mitter N. Silica vesicles as nanocarriers and adjuvants for generating both antibody and T-cell mediated immune resposes to Bovine Viral Diarrhoea Virus E2 protein. Biomaterials 2014; 35:9972-9983. [DOI: 10.1016/j.biomaterials.2014.08.044] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Accepted: 08/29/2014] [Indexed: 01/01/2023]
|
249
|
Evaluation of the immunogenicity and protective efficacy of Killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis. Med Microbiol Immunol 2014; 204:539-50. [DOI: 10.1007/s00430-014-0367-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Accepted: 11/18/2014] [Indexed: 10/24/2022]
|
250
|
Girard A, Roques E, Massie B, Archambault D. Flagellin in fusion with human rotavirus structural proteins exerts an adjuvant effect when delivered with replicating but non-disseminating adenovectors through the intrarectal route. Mol Biotechnol 2014; 56:394-407. [PMID: 24271565 DOI: 10.1007/s12033-013-9723-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Human rotavirus (HRV) is the worldwide leading cause of gastroenteritis in young children. Two live attenuated HRV vaccines have been approved since 2006. However, these live vaccines still have potential risks including reversion of virulence. Adenoviruses are suitable vectors for mucosal administration of subunit vaccines. In addition to the adjuvant effect of certain adenovirus components, the use of an adjuvant like flagellin is also another means to increase the immune response to the immunogen. The aim of this study was to determine whether flagellin in fusion with HRV structural proteins stimulates the innate immune response and enhances the HRV-specific immune response when delivered through the intrarectal route with replicating but non-disseminating adenovector (R-AdV). Salmonella typhimurium flagellin B (FljB) in fusion with HRV VP4Δ::VP7 protein induced IL-1β production in J774A.1 macrophages exposed to the R-AdV. Intrarectal administration of R-AdVs expressing either VP4Δ::VP7 or VP4Δ::VP7::FljB in BALB/c mice resulted in HRV-specific mixed Th1/Th2 immune responses. The HRV-specific antibody response elicited with the use of R-AdV expressing VP4Δ::VP7::FljB was higher than that with R-AdV expressing VP4Δ::VP7. The results also show that the replication capability of R-AdVs contributed to enhance the HRV-specific immune response as compared with that obtained with non-replicative AdVs. This work lays the foundation for using the R-AdV system and FljB-adjuvanted formulation to elicit a mucosal immune response specific to HRV.
Collapse
Affiliation(s)
- Aurélie Girard
- Department of Biological Sciences, University of Québec at Montréal, P.O. Box 8888, Succursale Centre-Ville, Montreal, QC, H3C 3P8, Canada
| | | | | | | |
Collapse
|